FDA 483 - Upsher-Smith LLC - August 08, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Upsher-Smith LLC identified significant deficiencies in their postmarketing adverse drug experience reporting. The firm failed to report several serious and unexpected adverse drug experiences to the FDA within the required 15-calendar-day timeframe, with delays extending over 300 days in some cases. Additionally, the firm lacked comprehensive written procedures for the surveillance and receipt of postmarketing adverse drug experiences, including those from social media, internal tracking systems, and contracted safety vendors.
- Person
ID · c4d77f7b-d6c2-471e-827e-308c939ea2c1